Authors:
Holloway, R
Shoulson, I
Fahn, S
Kieburtz, K
Lang, A
Marek, K
McDermott, M
Seibyl, J
Weiner, W
Welsh, M
Kamp, C
Day, D
Pahwa, R
Smith, D
McGuire, D
Barclay, L
Sutherland, L
Hildebrand, K
Hubble, J
Weeks, C
LeWitt, P
Mistura, K
Bloomfield, W
Miyasaki, J
Duff, J
Sime, E
Suchowersky, O
Argatoff, P
Andreas, Y
Kurth, M
Brewer, M
Russell, D
Fussell, B
Ford, B
Dillon, S
Hammerstad, J
Stone, C
Riley, D
Rainey, P
Standaert, D
Tennis, M
Wooten, F
Rost-Ruffner, E
Factor, S
Brown, D
Jankovic, J
Beach, J
Kurlan, R
Gardiner, I
Panisset, M
Amyot, D
Hall, J
Rajout, A
Wilson, W
McCullan, L
Brown, K
Clark, R
Rodnitzky, R
Dobson, J
Shults, C
Fontaine, D
Waters, C
Welsh, M
Pfeiffer, R
Rast, S
Bujak, G
Casaceli, C
Freimuth, A
Hodgeman, K
Honsinger, K
Watts, A
Hall, WJ
Leventhal, CM
Reich, S
Tariot, P
Balgoyen, D
Corak, D
Corrigan, M
Driver, M
Fraser, TJ
Lai, PY
Gomez-Mancilla, B
Munting, J
Peters, G
Rowland, C
Sullivan, H
Trasky, R
Wright, G
Berber, E
Morris, J
Mills, D
Hallak, L
Rines, S
Citation: R. Holloway et al., A randomized controlled trial comparing pramipexole with levodopa in earlyParkinson's disease: Design and methods of the CALM-PD study, CLIN NEUROP, 23(1), 2000, pp. 34-44
Authors:
Holloway, R
Shoulson, I
Kieburtz, K
McDermott, M
Tariot, P
Kamp, C
Day, D
Shinaman, A
Fahn, S
Lang, A
Marek, K
Seibyl, J
Weiner, W
Welsh, M
Pahwa, R
Coe, S
Barclay, L
Sutherland, L
Hildebrand, K
Hubble, J
Weeks, C
LeWitt, P
Miyasaki, J
Duff, J
Sime, E
Suchowersky, O
Stacy, M
Kurth, M
Brewer, M
Harrigan, M
Russell, DS
Fussell, B
Ford, B
Dillon, S
Hammerstad, J
Stone, C
Riley, D
Rainey, P
Standaert, D
Tennis, M
Wooten, F
Rost-Ruffner, E
Factor, S
Brown, D
Jankovic, J
Atassi, F
Kurlan, R
Gardiner, I
Panisset, M
Amyot, D
Hall, J
Rajput, A
Shirley, T
Rodnitzky, R
Dobson, J
Shults, C
Fontaine, D
Waters, C
Welsh, M
Schuman, S
Pfeiffer, R
Rast, S
Pfeiffer, B
Brocht, A
Casaceli, C
Daigneault, S
Hodgeman, K
Honsinger, K
O'Connell, C
Watts, A
Citation: R. Holloway et al., Pramipexole vs levodopa as initial treatment for Parkinson disease - A randomized controlled trial, J AM MED A, 284(15), 2000, pp. 1931-1938
Authors:
Shoulson, I
Greenamyre, T
Kieburtz, K
Schwid, S
McDermott, M
Kayson, E
Chase, T
Fahn, S
Lang, A
Penney, J
Hauser, R
Gauger, L
Kumar, R
Keable, L
Sime, E
Siemers, E
Belden, J
Pappert, EJ
Janko, K
Trugman, JM
Rost-Ruffner, E
Kurlan, R
Pearson, N
Carter, J
Nutt, J
Stone, C
Perlmutter, JS
McGee-Minnich, L
Freeman, A
Duddleston, C
Stacy, M
Brewer, M
Locke, B
Stern, M
Matthews, M
Friedman, J
Davies, R
Lannon, M
Grimes, D
Gray, P
Shults, C
Fontaine, D
O'Brien, C
Dingmann, C
Feigin, A
Mazurkiewicz, J
Elmer, L
Wernette, K
Singer, C
Bateman-Rodriguez, D
Carrion, A
Fernandez, M
Pfeiffer, R
Pfeiffer, B
Rast, S
Pahwa, R
McGuire, D
Brin, M
Walker, R
Casaceli, C
Day, D
Hodgeman, K
Huang, P
Orme, C
Sulimowicz, K
Watts, A
Means, E
Alderfer, V
Letizia, J
Craun, AM
Cooper, J
Holdich, T
Read, B
Citation: I. Shoulson et al., A multicenter randomized controlled trial of remacemide hydrochloride as monotherapy for PD, NEUROLOGY, 54(8), 2000, pp. 1583-1588
Citation: C. Shults et al., Fibroblast growth factor-2-producing fibroblasts protect the nigrostriataldopaminergic system from 6-hydroxydopamine, BRAIN RES, 883(2), 2000, pp. 192-204
Authors:
Brown, GG
Rahill, AA
Gorell, JM
McDonald, C
Brown, SJ
Sillanpaa, M
Shults, C
Citation: Gg. Brown et al., Validity of the dementia rating scale in assessing cognitive function in Parkinson's disease, J GER PSY N, 12(4), 1999, pp. 180-188
Authors:
Roman, MJ
Delis, DC
Filoteo, JV
Demadura, TL
Paulsen, J
Swerdlow, NR
Swenson, MR
Salmon, D
Butters, N
Shults, C
Citation: Mj. Roman et al., Is there a "subcortical" profile of attentional dysfunction? A comparison of patients with Huntington's and Parkinson's diseases on a global-local focused attention task", J CL EXP N, 20(6), 1998, pp. 873-884